Skip to main content

Table 1 Clinicopathological parameters of patients with pancreatic adenocarcinoma

From: GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival

Characteristics Patients
Age, years
 Mean 68.49 years ±11.59
 Range 40–93
Gender
 Male 23 (58.9%)
 Female 16 (41.1%)
BMI
 Mean 26.54 ± 5.155
 Range 17.30–36.03
ASA
 I 1 (2.6%)
 II 24 (61.5%)
 III 12 (30.8%)
 IV 1 (2.6%)
Comorbidities
 Hypertension 15 (38.5%)
 Diabetes Mellitus 8 (20.5%)
 Dislipemia 6 (15.4%)
 Smoker 16 (41%)
 Alcohol excess 8 (20.5%)
 Chronic pancreatitis 1 (2.6%)
 Other tumors in the past 2 (5.1%)
Symptoms
 Jaundice 33 (84.6%)
 Abdominal pain 7 (17.9%)
 Non induced weight loss 16 (41%)
 Nausea and vomiting 3 (7%)
 Pruritus 6 (15.4%)
 Fever of tumoral origin 1 (2.6%)
 Asthenia 1 (2.6%)
Size
 T1 1 (2.6%)
 T2 5 (12.8%)
 T3 33 (84.6%)
Lymph node
 N0 18 (46.2%)
 N1 21 (53.8%)
Differentiation
 Good 8 (20.5%)
 Moderate 20 (51.3%)
 Poor 10 (25.6%)
Stage
 IA 1 (2.6%)
 IB 3 (7.7%)
 IIA 15 (38.5%)
 IIB 20 (51.3%)